Patents by Inventor Andrew Youngs

Andrew Youngs has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Exendins and exendin agonists modified with albumin
    Patent number: 7608692
    Abstract: Modified exendins and exendin agonists having an exendin or exendin agonist linked to one or more polyethylene glycol polymers, for example, and related formulations and dosages and methods of administration thereof are provided. These modified exendins and exendin agonists, compositions and methods are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake.
    Type: Grant
    Filed: April 11, 2008
    Date of Patent: October 27, 2009
    Assignee: Amylin Pharmaceuticals, Inc.
    Inventors: Kathryn S. Prickett, Andrew A. Young
  • Biliary/Pancreatic Shunt Device and Method for Treatment of Metabolic and Other Diseases
    Publication number: 20090264808
    Abstract: Provided is a shunt device that promotes stimulation of secretion of intestinal L-cells and other enteroendocrine cell types. Enteroendocrine secretion is stimulated directly or indirectly by shunting bile and/or pancreatic secretion to segments of the gut more distal than would normally occur The shunt device may be a flexible catheter that is impervious to such secretions, with a proximal end draining the pancreatic/bile duct, and a distal end residing distally within the lumen of the small or large intestine. The shunt may be inserted with minimally invasive techniques, such as by endoscopy.
    Type: Application
    Filed: October 24, 2006
    Publication date: October 22, 2009
    Inventor: Andrew Young
  • Lyophilized Formulations of Exendins and Exendin Agonist Analogs
    Publication number: 20090215694
    Abstract: Novel formulations containing exendins, exendin agonists and/or exendin analogs are provided.
    Type: Application
    Filed: February 20, 2009
    Publication date: August 27, 2009
    Applicant: AMYLIN PHARMACEUTICALS, INC
    Inventors: Orville G. Kolterman, Andrew A. Young, James J. L'Italien
  • COMPOSITIONS AND METHODS FOR TREATING OBESITY AND RELATED METABOLIC DISORDERS
    Publication number: 20090209460
    Abstract: The present invention relates to the use of neuromedins in methods to treat and prevent conditions such as obesity and other food-related disorders. In addition, novel peptides, FNX Peptides, are provided, which find use in treating these disorders.
    Type: Application
    Filed: December 15, 2006
    Publication date: August 20, 2009
    Applicant: Amylin Pharmaceuticals, Inc.
    Inventors: Andrew A Young, Sarah L. McQuaid, Richard A. Pittner, Ved Srivastava
  • Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders
    Publication number: 20090181890
    Abstract: Methods and compositions for treating psychiatric diseases and disorders are disclosed. The methods provided generally involve the administration of an amylin or an amylin agonist to a subject in order to treat psychiatric diseases and disorders, and conditions associated with psychiatric diseases and disorders.
    Type: Application
    Filed: October 4, 2006
    Publication date: July 16, 2009
    Applicant: Amylin Pharmaceuticals , Inc.
    Inventors: Kevin D. Laugero, Michael R. Hanley, Christine M. Mack, David G. Parkes, Andrew A. Young
  • Exendin Agonist Analogs to Treat Diabetes
    Publication number: 20090176704
    Abstract: Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
    Type: Application
    Filed: August 29, 2008
    Publication date: July 9, 2009
    Applicant: Amylin Pharmaceuticals, Inc.
    Inventors: Nigel Robert Arnold Beeley, Kathryn S. Prickett, Sunil Bhavsar, Andrew Young
  • METHODS OF SEQUESTERING CO2
    Publication number: 20090169452
    Abstract: Methods of sequestering carbon dioxide (CO2) are provided. Aspects of the methods include precipitating a storage stable carbon dioxide sequestering product from an alkaline-earth-metal-containing water and then disposing of the product, e.g., by placing the product in a disposal location or using the product as a component of a manufactured composition. Also provided are systems for practicing methods of the invention.
    Type: Application
    Filed: December 24, 2008
    Publication date: July 2, 2009
    Inventors: Brent R. Constantz, Andrew Youngs, Philip Brian Tuet, Sidney Omelon, Kasra Farsad, Ryan J. Gilliam, Valentin Decker, Donald W. Kirk, J. Douglas Way, Allen J. Bard
  • Exendins and Exendin Agonist Analogs to Regulate Gastrointestinal Motility
    Publication number: 20090163423
    Abstract: Methods for reducing gastric motility and delaying gastric emptying for therapeutic and diagnostic purposes are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist. Methods for treating conditions associated with elevated, inappropriate, or undesired post-prandial blood glucose levels are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist alone or in conjunction with other anti-gastric emptying agents.
    Type: Application
    Filed: January 14, 2009
    Publication date: June 25, 2009
    Applicant: Amylin Pharmaceuticals, Inc.
    Inventors: Andrew A. Young, Bronislava Gedulin
  • Exendin pharmaceutical compositions
    Patent number: 7521423
    Abstract: Methods for reducing gastric motility and delaying gastric emptying for therapeutic and diagnostic purposes are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist. Methods for treating conditions associated with elevated, inappropriate, or undesired post-prandial blood glucose levels are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist alone or in conjunction with other anti-gastric emptying agents.
    Type: Grant
    Filed: July 20, 2004
    Date of Patent: April 21, 2009
    Assignee: Amylin Pharmaceuticals, Inc.
    Inventors: Andrew A. Young, Bronislava Gedulin
  • Methods of Treatment Using Exendin Peptides or GLP-1 Peptides
    Publication number: 20090054341
    Abstract: Methods for increasing urine flow are disclosed, comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. Methods for increasing urinary sodium excretion and decreasing urinary potassium concentration are also disclosed. The methods are useful for treating conditions or disorders associated with toxic hypervolemia, such as renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, and hypertension. The present invention also relates to methods for inducing an inotropic response comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. These methods are useful for treating conditions or disorders that can be alleviated by an increase in cardiac contractility such as congestive heart failure. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
    Type: Application
    Filed: October 7, 2008
    Publication date: February 26, 2009
    Applicant: Amylin Pharmaceuticals, Inc.
    Inventors: Andrew A. Young, Will Vine, Nigel R.A. Beeley, Kathryn Prickett
  • Water still and method of operation thereof
    Patent number: 7494572
    Abstract: A mechanical water still (10) includes an impervious dome-like upper surface (12) and a membrane base (14) that is coupled (26) to the impervious dome-like structure (12) to form, when inflated, a chamber (20). The membrane base (14) supports a water pervaporation process therethrough. A water collection well (16) has an opening into which water droplets condensed from the water pervaporation process collect. The water collection well (16) is sited within the membrane base (14) and generally extends outwardly and downwardly from the membrane base (14), as shown in FIG. 1. In use, a contaminated water source (24) is brought into, ideally, complete contact with the membrane base (14), with the water collection well (16) arranged both to act as a heat sink into the water source (24) and to provide stability to the water still (10) when floating and immersed in the water source (24).
    Type: Grant
    Filed: June 10, 2003
    Date of Patent: February 24, 2009
    Assignee: Design Technology and Innovation Ltd.
    Inventors: Mark Christopher Tonkin, Mark Andrew Young, Neil David Eckert
  • GIP ANALOG AND HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES
    Publication number: 20090036364
    Abstract: The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
    Type: Application
    Filed: February 10, 2006
    Publication date: February 5, 2009
    Applicant: Amylin Pharmaceuticals, Inc.
    Inventors: Odile Esther Levy, Alain D. Baron, Lawrence J D'Souza, Mary Erickson, Soumitra S. Ghosh, Michael R. Hanley, Samuel Janssen, Carolyn M. Jodka, Diana Y. Lewis, Christine M. Mack, David G. Parkes, Richard A. Pittner, Christopher J. Soares, Ved Srivastava, Andrew A. Young
  • GIP ANALOG AND HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES
    Publication number: 20080312157
    Abstract: The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
    Type: Application
    Filed: August 17, 2007
    Publication date: December 18, 2008
    Applicant: Amylin Pharmaceuticals, Inc.
    Inventors: Odile Esther Levy, Alain D. Baron, Lawrence J. D'Souza, Mary Erickson, Soumitra S. Ghosh, Michael R. Hanley, Samuel Janssen, Carolyn M. Jodka, Diana Y. Lewis, Christine M. Mack, David G. Parkes, Richard A. Pittner, Christopher J. Soares, Ved Srivastava, Andrew A. Young, Thao Le
  • Amylin and Amylin Agonists For Treating Psychiatric Diseases and Disorders
    Publication number: 20080287355
    Abstract: Methods and compositions for treating psychiatric diseases and disorders are disclosed. The methods provided generally involve the administration of an amylin or an amylin agonist to a subject in order to treat psychiatric diseases and disorders, and conditions associated with psychiatric diseases and disorders.
    Type: Application
    Filed: March 31, 2006
    Publication date: November 20, 2008
    Applicant: Amylin Pharmaceuticals, Inc.
    Inventors: Kevin D. Laugero, Michael R. Hanley, Christine M. Mack, David G. Parkes, Andrew A. Young
  • Inotropic and diuretic effects of GLP-1 and GLP-1 agonists
    Patent number: 7442680
    Abstract: Methods for increasing urine flow are disclosed, comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. Methods for increasing urinary sodium excretion and decreasing urinary potassium concentration are also disclosed. The methods are useful for treating conditions or disorders associated with toxic hypervolemia, such as renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, and hypertension. The present invention also relates to methods for inducing an inotropic response comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. These methods are useful for treating conditions or disorders that can be alleviated by an increase in cardiac contractility such as congestive heart failure. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
    Type: Grant
    Filed: September 5, 2003
    Date of Patent: October 28, 2008
    Assignee: Amylin Pharmaceuticals, Inc.
    Inventors: Andrew A. Young, Will Vine, Nigel R. A. Beeley, Kathryn Prickett
  • Exendin Analog Formulations
    Publication number: 20080249018
    Abstract: Novel formulations containing exendins, exendin agonists and/or exendin analogs are provided
    Type: Application
    Filed: April 10, 2008
    Publication date: October 9, 2008
    Applicant: Amylin Pharmaceuticals, Inc.
    Inventors: Orville G. KOLTERMAN, Andrew A. YOUNG, James J. L'ITALIEN
  • Exendins and Exendin Agonists Modified with Albumin
    Publication number: 20080214467
    Abstract: Novel modified exendins and exendin agonists having an exendin or exendin agonist linked to one or more molecular weight increasing compounds, for example, albumin, polyethylene glycol polymers, and related formulations and dosages and methods of administration thereof are provided. These modified exendins and exendin agonists, compositions and methods are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake.
    Type: Application
    Filed: April 11, 2008
    Publication date: September 4, 2008
    Applicant: Amylin Pharmaceuticals, Inc.
    Inventors: Kathryn S. PRICKETT, Andrew A. Young
  • Use of exendins and agonists thereof to treat diabetes
    Patent number: 7419952
    Abstract: Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
    Type: Grant
    Filed: March 3, 2006
    Date of Patent: September 2, 2008
    Assignee: Amylin Pharmaceuticals, Inc.
    Inventors: Nigel Robert Arnold Beeley, Kathryn S. Prickett, Sunil Bhavsar, Andrew A. Young
  • Amylin Family Polypeptide-6 (Afp-6) Analogs and Methods of Making and Using Them
    Publication number: 20080207501
    Abstract: The present invention relates to Amylin Family Polypeptide-6 (AFP-6) analogs, which include derivatives and fragments, related nucleic acids, expression constructs, host cells, and processes for recombinant production of the AFP-6 analogs. The AFP-6 analogs of the invention include one or more amino acid sequence modifications. In addition, methods and compositions are disclosed to treat and prevent conditions such as metabolic and cardiovascular disorders, e.g., obesity, diabetes, metabolic syndrome, myocardial ischemia, and increased cardiovascular risk.
    Type: Application
    Filed: October 11, 2005
    Publication date: August 28, 2008
    Applicant: Amylin Pharmaceuticals, Inc.
    Inventors: Mary Erickson, Ved Srivastava, Sarah McQuaid, Andrew A. Young, Richard A. Pittner, Soumitra S. Ghosh
  • Exendins and Exendin Agonists Modified with Polyamino Acids
    Publication number: 20080200390
    Abstract: Novel modified exendins and exendin agonists having an exendin or exendin agonist linked to one or more molecular weight increasing compounds, for example, polyamino acids, polyethylene glycol polymers, and related formulations and dosages and methods of administration thereof are provided. These modified exendins and exendin agonists, compositions and methods are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake.
    Type: Application
    Filed: April 11, 2008
    Publication date: August 21, 2008
    Applicant: Amylin Pharmaceuticals, Inc.
    Inventors: Kathryn S. PRICKETT, Andrew A. Young